Amitriptyline Pharmacogenetics - Genetic Drug Testing Gene2Rx

Drug Overview

Amitriptyline (brand name Elavil) is a tricyclic antidepressant first approved in the 1960s. It is widely used for the treatment of major depressive disorder. Off-label, it may be prescribed for neuropathic pain, migraine prophylaxis, and chronic tension headaches.

The drug is indicated primarily for depression. Clinicians also use lower doses for neuropathic pain and migraine prevention, where it tends to help even at exposures below the antidepressant threshold.

Amitriptyline works by inhibiting the reuptake of serotonin and norepinephrine at nerve terminals, increasing their availability in the synaptic cleft. This modulation of neurotransmitter levels helps improve mood and pain signals over time.

Relevant Genes and Their Roles

Two liver enzymes do the bulk of the work clearing amitriptyline: CYP2D6 and CYP2C19. CYP2D6 mostly converts the tertiary amine (amitriptyline) into less active compounds; CYP2C19 also breaks it down and contributes to the conversion of tertiary amines into secondary amines like nortriptyline.

Variants in either gene change how quickly amitriptyline is broken down. The terms poor, intermediate, normal, rapid, and ultrarapid metabolizer describe how active your version of the enzyme is. Poor metabolizers run slow, so the drug accumulates and side effects get worse. Ultrarapid metabolizers run fast, so standard doses may not build up enough to work.

Impact of Genetics on Drug Response

Your CYP2D6 and CYP2C19 phenotypes together determine how much amitriptyline ends up in your bloodstream at a given dose. That changes both whether the drug works and how well you tolerate it. Knowing the phenotype before prescribing lets the dose match the patient, or points to an alternative drug when neither pathway works well.

Expected Clinical Effects of Genetic Variation

Individuals fall into one of several metabolizer categories based on their CYP2D6 and CYP2C19 genotypes. These categories predict amitriptyline exposure and associated benefits or risks.

Ultrarapid/Rapid Metabolizer

Effect on drug levels: Lower than expected plasma concentrations.
Clinical consequence: Increased risk of treatment failure or sub-optimal response.
Side effects: Generally fewer side effects; efficacy may be reduced.

Normal Metabolizer

Effect on drug levels: Expected therapeutic range.
Clinical consequence: Typical efficacy and tolerability.
Side effects: As described in the drug label; moderate frequency.

Intermediate Metabolizer

Effect on drug levels: Moderately increased plasma concentrations.
Clinical consequence: Higher likelihood of dose-related side effects.
Side effects: Increased risk of anticholinergic effects (dry mouth, sedation).

Poor Metabolizer

Effect on drug levels: Significantly elevated plasma concentrations.
Clinical consequence: Higher risk of toxicity and anticholinergic side effects.
Side effects: Severe sedation, confusion, cardiac conduction changes.

Indeterminate/Not Available

Effect on drug levels: Unknown.
Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring.
Side effects: Unknown; monitor for typical TCA adverse effects.

Dosing Guidelines

The following dosing guidelines are based on the available guidelines for amitriptyline from the Clinical Pharmacogenetics Implementation Consortium (CPIC).

CYP2D6 Dosing Guideline

Phenotype	Clinical Consequence	Guideline Recommendation
Ultrarapid Metabolizer	Lower plasma concentrations; risk of therapeutic failure	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, titrate to a higher target dose and utilize therapeutic drug monitoring.
Normal Metabolizer	Expected metabolism and exposure	Initiate therapy with recommended starting dose.
Intermediate Metabolizer	Moderately increased exposure; higher side-effect risk	Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring.
Poor Metabolizer	Significantly increased exposure; high side-effect risk	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider 50% dose reduction and utilize therapeutic drug monitoring.
Indeterminate	Unknown impact	Initiate therapy with recommended starting dose.
Not available	Unknown impact	Initiate therapy with recommended starting dose.

CYP2C19 Dosing Guideline

Phenotype	Clinical Consequence	Guideline Recommendation
Ultrarapid Metabolizer	Increased conversion of tertiary to secondary amines; potential sub-optimal response	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19 (e.g., nortriptyline, desipramine). If a tertiary amine is warranted, utilize therapeutic drug monitoring.
Rapid Metabolizer	Increased conversion; potential sub-optimal response	Avoid tertiary amine use; consider alternatives not metabolized by CYP2C19. Utilize therapeutic drug monitoring if needed.
Normal Metabolizer	Expected metabolism and exposure	Initiate therapy with recommended starting dose.
Intermediate Metabolizer	Reduced metabolism; slightly higher exposure	Initiate therapy with recommended starting dose.
Poor Metabolizer	Greatly reduced conversion; potential for increased side effects	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. For tertiary amines, consider 50% dose reduction and utilize therapeutic drug monitoring.
Likely Intermediate Metabolizer	Reduced metabolism; slightly higher exposure	Initiate therapy with recommended starting dose.
Likely Poor Metabolizer	Greatly reduced conversion; potential for increased side effects	Avoid tertiary amine use; consider alternative drug not metabolized by CYP2C19. For tertiary amines, consider 50% dose reduction and utilize therapeutic drug monitoring.
Indeterminate	Unknown impact	Initiate therapy with recommended starting dose.
Not available	Unknown impact	Initiate therapy with recommended starting dose.

Alternative Treatment Options

Examples of alternative therapies include secondary amine tricyclics such as nortriptyline and desipramine, which are less dependent on CYP2C19 metabolism. Other options may include non-TCA antidepressants (e.g., SSRIs) not significantly metabolized by CYP2D6 or CYP2C19. These are provided as examples; clinical decisions should be individualized.

Sources and References

CPIC – Guideline for tricyclic antidepressants and CYP2D6 and CYP2C19

Considering GeneSight for this medication?

Gene2Rx uses the same CPIC and FDA guidelines as GeneSight, covers more medications, costs $5-$49 instead of several hundred, and works with the 23andMe or AncestryDNA data you may already have. See the full side-by-side comparison before ordering.

Read the comparison →

Genes that affect Amitriptyline

See the full list of drugs affected by each gene:

Brand names containing Amitriptyline

See how your genetics affect each product Amitriptyline shows up in:

Elavil

Brand of amitriptyline

Related Guides

Learn more about how genetics may affect your response to Amitriptyline and related medications: